Trade Names:
Synonyms:
Status: Approved (2018)
Entry Type: Oligonucleotide
Molecule Category: Salt
UNII: WO0YM16LKG
Parent Compound: PATISIRAN

Pharmacology

Action Mechanism of Action Reference
RNAI INHIBITOR Transthyretin mRNA RNAi inhibitor FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Amyloid Neuropathies, Familial 4 D028227 FDA

Related Entries

Parent

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
23.28
Nervous system disorders
12.35
Injury, poisoning and procedural complications
8.24
Cardiac disorders
7.61
Psychiatric disorders
5.91
Musculoskeletal and connective tissue disorders
5.82
Gastrointestinal disorders
5.46
Skin and subcutaneous tissue disorders
4.74
Vascular disorders
4.66
Respiratory, thoracic and mediastinal disorders
4.39
Immune system disorders
3.58
Investigations
3.22
Infections and infestations
2.78
Metabolism and nutrition disorders
2.69

Cross References

Resources Reference
ChEMBL CHEMBL4297536
FDA SRS WO0YM16LKG